Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29625406 | 1.00 | PARP1 (0.54) | PARP1NPC1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL23079145 | 0.85 | GSK3B (0.42) | PARP1CHEK1CHEK2POLBMAPK1 | |
| SCHEMBL1520075 | 0.85 | PARP1 (0.64) | PARP1CYP11B1CYP11B2TRPA1CHEK2 | |
| SCHEMBL6206600 | 0.85 | ABCG2 (0.44) | POLBMAPK1KDM4EALDH1A1LMNA | |
| SCHEMBL30457603 | 0.84 | MAOB (0.42) | PARP1POLBMAPK1KDM4EALDH1A1 | |
| SCHEMBL30456847 | 0.84 | MAOB (0.42) | PARP1POLBMAPK1KDM4EALDH1A1 | |
| SCHEMBL340702 | 0.83 | KDM4C (0.52) | POLBMAPK1KDM4EALDH1A1LMNA | |
| SCHEMBL29442138 | 0.83 | KDM4C (0.52) | POLBMAPK1KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9236405 | 0.81 | KDM4C (0.51) | POLBMAPK1KDM4EALDH1A1LMNA | |
| SCHEMBL340356 | 0.81 | KDM4E (0.44) | NPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912617-A | Substituted tricycles and methods of use | 艾伯维公司 | 2022-01-11 | — | — | CN | claimed |
| CN-109195965-A | The inhibitor that WDR5 protein-protein combines | 普罗佩纶治疗公司 | 2019-01-11 | — | — | CN | claimed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | claimed |
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | claimed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113912617-A | Substituted tricycles and methods of use | 艾伯维公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-113845439-A | Bibenzamide CXCR4 antagonist and preparation and application thereof | 杭州师范大学 | 2021-12-28 | — | — | CN | disclosed |
| CN-108349930-B | Substituted tricycles and methods of use | 艾伯维公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-112218850-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | disclosed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199816-A1 | Aryl sulfonyl piperidines | GILLESPIE PAUL | 2006-09-07 | — | — | US | disclosed |
| WO-2004065389-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE | XENOVA LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
| EP-1037633-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC (CA) | 2000-09-27 | — | — | EP | disclosed |
| EP-0984967-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC (CA) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | disclosed |
| WO-1997034894-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC. (CA) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199816-A1 | Aryl sulfonyl piperidines | GPR119, SLC5A2, GLS2 | PARP1 4324/4885NPC1 234/4885RAB9A 1672/4885 |
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | PARP1 3617/4885NPC1 889/4885RAB9A 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.